Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT05898464
PHASE4
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
Sponsor: Seoul National University Hospital
View on ClinicalTrials.gov
Summary
The purpose of this study is to compare the immunogenicity and safety of recombinant zoster vaccine according to CD4+ T-cell count and age in people living with HIV, and to provide evidence to guide immunization of people living with HIV.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
71
Start Date
2023-06-27
Completion Date
2026-02-10
Last Updated
2026-04-27
Healthy Volunteers
No
Interventions
BIOLOGICAL
Recombinant zoster vaccination
Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
Locations (2)
Seoul National University Hospital
Seoul, South Korea
National Medical Center
Seoul, South Korea